Identification of serum biomarkers for ovarian cancer using MALDI-TOF-MS combined with magnetic beads.
Summary of "Identification of serum biomarkers for ovarian cancer using MALDI-TOF-MS combined with magnetic beads."
BACKGROUND:
The objective of this study was to search for potential protein biomarkers in serum for diagnosis of ovarian cancer, by use of proteomic fingerprint techniques.
METHOD:
MALDI-TOF-MS was combined with magnetic beads to profile and compare serum protein spectra from 40 ovarian cancer patients and from 60 healthy controls.
RESULTS:
The tree analysis model of potential cancer biomarkers was constructed with Biomarker Patterns software on the basis of three identified biomarkers (5486, 6440, and 13720 Da), resulting in excellent discrimination between the ovarian cancer and non-cancer in our tests. The sensitivity was 90% and the specificity was 86.7%. In a blind test the sensitivity was 88% and the specificity was 83.3%.
CONCLUSION:
The results suggested that biomarkers for ovarian cancer diagnosis in serum could be identified by MALDI-TOF-MS combined with the use of magnetic beads. The use of combined biomarkers would further enable powerful and reliable diagnosis of ovarian cancer with high sensitivity and specificity.
Affiliation
Sir Run Run Shaw Hospital, Medical School, Zhejiang University, Hangzhou, Zhejiang, China, shengjun_wu@126.com.
Journal Details
This article was published in the following journal.
Name: International journal of clinical oncology / Japan Society of Clinical Oncology
ISSN: 2547-7772
Pages:
Links
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/21638024
- DOI: http://dx.doi.org/10.1007/s10147-011-0259-6
Medical and Biotech [MESH] Definitions
National Cancer Institute (u.s.)
Component of the NATIONAL INSTITUTES OF HEALTH. Through basic and clinical biomedical research and training, it conducts and supports research with the objective of cancer prevention, early stage identification and elimination. This Institute was established in 1937.
Serum Bactericidal Antibody Assay
Procedures for identification and measurement of IMMUNOGLOBULINS in the blood that initiate lysis of bacteria.
Topotecan
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.
Ovarian Failure, Premature
Cessation of ovarian function after MENARCHE but before the age of 40, without or with OVARIAN FOLLICLE depletion. It is characterized by the presence of OLIGOMENORRHEA or AMENORRHEA, elevated GONADOTROPINS, and low ESTRADIOL levels. It is a state of female HYPERGONADOTROPIC HYPOGONADISM. Etiologies include genetic defects, autoimmune processes, chemotherapy, radiation, and infections.
Primary Ovarian Insufficiency
Cessation of ovarian function after MENARCHE but before the age of 40, without or with OVARIAN FOLLICLE depletion. It is characterized by the presence of OLIGOMENORRHEA or AMENORRHEA, elevated GONADOTROPINS, and low ESTRADIOL levels. It is a state of female HYPERGONADOTROPIC HYPOGONADISM. Etiologies include genetic defects, autoimmune processes, chemotherapy, radiation, and infections.
PubMed Articles
AGR2, a mucinous ovarian cancer marker, promotes cell proliferation and migration.
Ovarian cancer is a leading cause of death in women. Early detection of ovarian cancer is essential to decrease mortality. However, the early diagnosis of ovarian cancer is difficult due to a lack of...
Ovarian Cancer: Biomarker Proteomic Diagnosis in Progress.
Ovarian cancer lacks clear syndromes at an early stage and could result in serious problem in woman's health status. The current diagnostic approach relies on physical examination, ultrasound examinat...
Background: Among biomarkers, cancer-antigen 125 (CA-125) is the most studied. We propose an analytical tool to track ovarian carcinoma biomarkers, that is, the MALDI mass spectrometry imaging. Materi...
Ovarian cancer is a gynecological malignancy with the highest mortality. Chemoresistance is an important subject for the treatment of ovarian cancer, because obtaining significant drug resistance to t...
Leucine-rich alpha-2-glycoprotein-1 is Upregulated in Sera and Tumors of Ovarian Cancer Patients.
ABSTRACT: BACKGROUND: New biomarkers that replace or are used in conjunction with the current ovarian cancer diagnostic antigen, CA125, are needed for detection of ovarian cancer in the presurgical se...
Clinical Trials
RATIONALE: Studying samples of exhaled breath from patients with ovarian epithelial cancer, polycystic ovarian syndrome, or endometriosis and from healthy participants in the laboratory ma...
Identification of Biomarkers Associated With Human Hepatocellular Carcinoma by SELDI
Hepatocellular carcinoma (HCC) has been the leading cause of cancer death in Taiwan. Though Alpha-fetoprotein (AFP) and des-γ-carboxy prothrombin(DCP) are used as the tumor markers for di...
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with a high risk of developing ovarian cancer may help doctors identify and learn more about biomarkers rela...
Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma
The objective of the study is to identify novel blood markers for the diagnosis of liver cancer. We will collect serum samples from consented patients and measure the levels of potential p...
CA 125 Algorithm for the Early Detection of Ovarian Cancer
The goal of this clinical research study is to evaluate a method involving a blood test, called CA-125, that may be helpful in the early detection of ovarian cancer in post-menopausal wome...
